Lv4
690 积分 2023-05-06 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
24天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
30天前
已完结
Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors
7个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
9个月前
已完结
Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection
1年前
已完结
Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells
1年前
已完结
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
1年前
已完结
Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication
1年前
已完结
皖公网安备34019202002308
